Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

FT819 in Subjects With B-cell Malignancies

NCT04629729

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +20 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Arizona Phoenix, Arizona, United States
  • UC Davis Davis, California, United States
  • Scripps Green Hospital La Jolla, California, United States
View all 18 locations
View Trial Details
Active, not recruiting

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

NCT04635384

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Bone Marrow Diseases, +15 more
Locations
  • University of California Irvine Brisbane, California, United States
  • City of Hope Duarte, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Georgia Cancer Center at Augusta University Augusta, Georgia, United States
View Trial Details
Active, not recruiting

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

NCT03478462

Conditions
Astrocytoma, Brain Diseases, Brain Neoplasms, +62 more
Locations
  • Lucile Packard Children's Hospital Palo Alto, California, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Duke University Chapel Hill, North Carolina, United States
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
View Trial Details
Active, not recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Arkansas Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health Moores Cancer Center San Diego, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 106 locations
View Trial Details

Related conditions